Drug Interactions between Rifadin and spironolactone
This report displays the potential drug interactions for the following 2 drugs:
- Rifadin (rifampin)
- spironolactone
Interactions between your drugs
No interactions were found between Rifadin and spironolactone. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Rifadin
A total of 718 drugs are known to interact with Rifadin.
- Rifadin is in the drug class rifamycin derivatives.
- Rifadin is used to treat the following conditions:
spironolactone
A total of 379 drugs are known to interact with spironolactone.
- Spironolactone is in the following drug classes: aldosterone receptor antagonists, potassium-sparing diuretics.
-
Spironolactone is used to treat the following conditions:
- Acne (off-label)
- Alcohol Use Disorder (off-label)
- Alopecia (off-label)
- Edema
- Gender Dysphoria (off-label)
- Heart Failure
- High Blood Pressure
- Hirsutism
- Hypokalemia
- Primary Hyperaldosteronism
- Primary Hyperaldosteronism Diagnosis
Drug and food interactions
rifAMPin food
Applies to: Rifadin (rifampin)
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Concurrent use of rifampin in patients who ingest alcohol daily may result in an increased incidence of hepatotoxicity. The increase in hepatotoxicity may be due to an additive risk as both alcohol and rifampin are individually associated with this adverse reaction. However, the exact mechanism has not been established.
ADJUST DOSING INTERVAL: Administration with food may reduce oral rifampin absorption, increasing the risk of therapeutic failure or resistance. In a randomized, four-period crossover phase I study of 14 healthy male and female volunteers, the pharmacokinetics of single dose rifampin 600 mg were evaluated under fasting conditions and with a high-fat meal. Researchers observed that administration of rifampin with a high-fat meal reduced rifampin peak plasma concentration (Cmax) by 36%, nearly doubled the time to reach peak plasma concentration (Tmax) but reduced overall exposure (AUC) by only 6%.
MANAGEMENT: The manufacturer of oral forms of rifampin recommends administration on an empty stomach, 30 minutes before or 2 hours after meals. Patients should be encouraged to avoid alcohol or strictly limit their intake. Patients who use alcohol and rifampin concurrently or have a history of alcohol use disorder may require additional monitoring of their liver function during treatment with rifampin.
References
- "Product Information. Rifampin (rifAMPin)." Akorn Inc (2022):
- "Product Information. Rifampicin (rifampicin)." Mylan Pharmaceuticals Inc (2022):
- "Product Information. Rifadin (rifampicin)." Sanofi (2023):
- "Product Information. Rifadin (rifaMPICin)." Sanofi-Aventis Australia Pty Ltd (2024):
- Peloquin CA, Namdar R, Singleton MD, Nix DE "Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids https://pubmed.ncbi.nlm.nih.gov/9925057/" (2024):
- "Product Information. Rofact (rifampin)." Bausch Health, Canada Inc. (2019):
spironolactone food
Applies to: spironolactone
Spironolactone and ethanol may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.